Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RidgetechFRA:7QL 39 3-Year EPS without NRI Growth Rate is 83.00% as of Mar. 2026, which is 276% above its 10-year median of 22.05. GuruFocus rates FRA:7QL with a GF Score™ of 39/100 and a GF Value™ of €1,300,356.14. The stock has 3 warning signs investors should review. Among 505 Healthcare Providers & Services companies, Ridgetech ranks better than 94.26% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 83.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Ridgetech was 83.00% per year. The lowest was -55.00% per year. And the median was 22.05% per year.
Ridgetech (FRA:7QL) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ridgetech 3-Year EPS without NRI Growth Rate Related Terms
FRA:7QL vs BLMH, DHTI, HEWA: 3-Year EPS without NRI Growth Rate Comparison
For the Pharmaceutical Retailers subindustry, Ridgetech's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ridgetech 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ridgetech's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ridgetech's 3-Year EPS without NRI Growth Rate falls into.
Ridgetech 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 83.00% mean?
Ridgetech (FRA:7QL) has a 3-Year EPS without NRI Growth Rate of 83.00% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ridgetech and its competitors. This is 276% above median its historical median of 22.05. According to the industry distribution chart, Ridgetech ranks #29 out of 505 companies in the Healthcare Providers & Services industry, placing it in the top 5.7%.
Is Ridgetech's 3-Year EPS without NRI Growth Rate too high?
Ridgetech's current 3-Year EPS without NRI Growth Rate of 83.00% is 276% above median its 10-year median of 22.05. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 11.00. Ridgetech's value of 83.00% is 654.5% above this industry median. Based on the distribution chart, Ridgetech ranks #29 out of 505 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Ridgetech has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Ridgetech's 3-Year EPS without NRI Growth Rate compare to BLMH and DHTI?
According to the Healthcare Providers & Services industry distribution chart, Ridgetech ranks #29 out of 505 companies for 3-Year EPS without NRI Growth Rate. This places Ridgetech in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 11.00. Ridgetech's value of 83.00% is 654.5% above this benchmark. While the company's 10-year median is 22.05 vs. the industry median of 11.00, Ridgetech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.00, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ridgetech's current 3-Year EPS without NRI Growth Rate of 83.00% is 654.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ridgetech and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ridgetech's current 3-Year EPS without NRI Growth Rate is 83.00%, which is 276% above median its own 10-year median of 22.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ridgetech stock overvalued right now?
Ridgetech (FRA:7QL) has a current 3-Year EPS without NRI Growth Rate of 83.00%. The stock's GF Value™ is €1,300,356.14, compared to a current price of €20,304.00 — trading 98.4% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 83.00%, which is 276% above median its 10-year median of 22.05 and 654.5% above the Healthcare Providers & Services industry median of 11.00. Ridgetech's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ridgetech (FRA:7QL), the current 3-Year EPS without NRI Growth Rate is 83.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ridgetech (FRA:7QL) Overvalued in 2026?
Based on GuruFocus' analysis, Ridgetech stock appears to be undervalued.
The current stock price of €20,304.00 is trading 98.4% below its estimated GF Value™ of €1,300,356.14.
Key valuation signals for FRA:7QL:
3-Year EPS without NRI Growth Rate: 83.00% (276% above median its 10-year median of 22.05)
GF Value™: €1,300,356.14 vs. price of €20,304.00 (98.4% below fair value)
Industry Position: 654.5% above the Healthcare Providers & Services median (#29 of 505)
No single metric tells the full story. See the FRA:7QL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ridgetech Inc formerly China Jo-Jo Drugstores Inc is a retailer and distributor of pharmaceutical products. The company's operating segments include Retail drugstores, Online Pharmacy, and Drug wholesale. Retail drugstores segment sells prescription and over-the-counter medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy segment sells drugs through third-party platforms such as Alibaba's Tmall, JD.com, and Amazon.com. It generates maximum revenue from the Retail drugstores segment.
39GF Score
Get the complete analysis for FRA:7QL
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7QL has been successfully added to your 
